Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma – Pipeline Review, H1 2017, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.
Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Mesothelioma – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Malignant Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 30, 27, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 7 and 6 molecules, respectively.
Malignant Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Malignant Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Malignant Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Malignant Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Mesothelioma (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Malignant Mesothelioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Malignant Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Aduro BioTech Inc
Advantagene Inc
Amphera BV
AnGes MG Inc
arGEN-X BV
ArQule Inc
AVEO Pharmaceuticals Inc
Bayer AG
Biogen Inc
Bionomics Ltd
Biotecnol Ltd
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Company
Calithera Biosciences Inc
CanBas Co Ltd
CBT Pharmaceuticals Inc
Concordia International Corp
Eagle Pharmaceuticals Inc
Eisai Co Ltd
Eli Lilly and Company
EnGeneIC Ltd
EpiZyme Inc
F. Hoffmann-La Roche Ltd
Five Prime Therapeutics Inc
Genelux Corp
GlaxoSmithKline Plc
Horizon Pharma Plc
Inventiva
Juno Therapeutics Inc
Karyopharm Therapeutics Inc
MacroGenics Inc
MedImmune LLC
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
MolMed SpA
Morphotek Inc
Novartis AG
Ono Pharmaceutical Co Ltd
OSE Immunotherapeutics
Oxford BioMedica Plc
Pharma Mar SA
Philogen SpA
Polaris Pharmaceuticals Inc
Progenra Inc
Seattle Genetics Inc
Sellas Inc
Targovax ASA
TRACON Pharmaceuticals Inc
TREAT U SA
UbiVac LLC
VasGene Therapeutics Inc
Verastem Inc
Virttu Biologics Ltd
Vyriad Inc
Y's Therapeutics Co Ltd
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 10
Global Markets Direct Report Coverage 10
Malignant Mesothelioma – Overview 11
Malignant Mesothelioma – Therapeutics Development 12
Pipeline Overview 12
Pipeline by Companies 13
Pipeline by Universities/Institutes 18
Products under Development by Companies 19
Products under Development by Universities/Institutes 24
Malignant Mesothelioma – Therapeutics Assessment 25
Assessment by Target 25
Assessment by Mechanism of Action 30
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Malignant Mesothelioma – Companies Involved in Therapeutics Development 39
Aduro BioTech Inc 39
Advantagene Inc 39
Amphera BV 40
AnGes MG Inc 40
arGEN-X BV 41
ArQule Inc 41
AVEO Pharmaceuticals Inc 42
Bayer AG 42
Biogen Inc 43
Bionomics Ltd 43
Biotecnol Ltd 44
Boehringer Ingelheim GmbH 44
Boston Biomedical Inc 45
Bristol-Myers Squibb Company 45
Calithera Biosciences Inc 46
CanBas Co Ltd 46
CBT Pharmaceuticals Inc 47
Concordia International Corp 47
Eagle Pharmaceuticals Inc 48
Eisai Co Ltd 48
Eli Lilly and Company 49
EnGeneIC Ltd 49
EpiZyme Inc 50
F. Hoffmann-La Roche Ltd 50
Five Prime Therapeutics Inc 51
Genelux Corp 51
GlaxoSmithKline Plc 52
Horizon Pharma Plc 52
Inventiva 53
Juno Therapeutics Inc 53
Karyopharm Therapeutics Inc 54
MacroGenics Inc 54
MedImmune LLC 55
Merck & Co Inc 55
Merck KGaA 56
Millennium Pharmaceuticals Inc 56
MolMed SpA 57
Morphotek Inc 57
Novartis AG 58
Ono Pharmaceutical Co Ltd 59
OSE Immunotherapeutics 59
Oxford BioMedica Plc 60
Pharma Mar SA 60
Philogen SpA 61
Polaris Pharmaceuticals Inc 61
Progenra Inc 62
Seattle Genetics Inc 62
Sellas Inc 63
Targovax ASA 63
TRACON Pharmaceuticals Inc 64
TREAT U SA 64
UbiVac LLC 65
VasGene Therapeutics Inc 65
Verastem Inc 66
Virttu Biologics Ltd 66
Vyriad Inc 67
Y's Therapeutics Co Ltd 67
Malignant Mesothelioma – Drug Profiles 68
(epirubicin + staurosporine) – Drug Profile 68
alisertib – Drug Profile 69
amatuximab – Drug Profile 75
anetumab ravtansine – Drug Profile 78
ARGX-110 – Drug Profile 81
atezolizumab – Drug Profile 86
AV-203 – Drug Profile 103
avelumab – Drug Profile 106
bevacizumab – Drug Profile 115
BG-00001 – Drug Profile 127
birabresib – Drug Profile 128
BMS-986148 – Drug Profile 131
BNC-105 – Drug Profile 132
brentuximab vedotin – Drug Profile 138
CB-839 – Drug Profile 165
CBP-501 – Drug Profile 174
CBT-501 – Drug Profile 177
Cellular Immunotherapy for Oncology – Drug Profile 178
Cellular Immunotherapy to Target Mesothelin for Malignant Pleural Mesothelioma and Advanced Leukemia – Drug Profile 179
Cellular Immunotherapy to Target Mesothelin for Oncology – Drug Profile 180
Cellular Immunotherapy to Target WT1 for Oncology – Drug Profile 181
cisplatin – Drug Profile 182
CRS-207 – Drug Profile 183
CSG-MESO – Drug Profile 190
defactinib hydrochloride – Drug Profile 191
DFP-10825 – Drug Profile 199
doxorubicin hydrochloride – Drug Profile 200
DPV-001 – Drug Profile 201
durvalumab – Drug Profile 203
durvalumab + tremelimumab – Drug Profile 217
E-7449 – Drug Profile 223
emactuzumab – Drug Profile 224
enoblituzumab – Drug Profile 225
ESK-1 – Drug Profile 228
FL-118 – Drug Profile 229
FP-1039 – Drug Profile 232
galinpepimut-S – Drug Profile 236
ganetespib – Drug Profile 240
GEN-0101 – Drug Profile 254
Gene Therapy for Glioblastoma and Mesothelioma – Drug Profile 256
Gene Therapy for Malignant Pleural Effusion and Solid Tumors – Drug Profile 257
Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma – Drug Profile 258
GLONC-1 – Drug Profile 259
GSK-2256098 – Drug Profile 263
GSK-3359609 – Drug Profile 265
HSV-1716 – Drug Profile 266
HXR-9 – Drug Profile 270
iCasp9M28z – Drug Profile 271
interferon gamma-1b – Drug Profile 272
ipilimumab + nivolumab – Drug Profile 277
JTCR-016 – Drug Profile 281
KPT-251 – Drug Profile 283
KPT-276 – Drug Profile 284
LEU-001 – Drug Profile 285
lurbinectedin – Drug Profile 286
LY-3023414 – Drug Profile 294
MesoCancerVac – Drug Profile 296
MesoCART – Drug Profile 297
MGD-009 – Drug Profile 298
Monoclonal Antibody Conjugate to Target Mesothelin for Malignant Mesothelioma – Drug Profile 300
Monoclonal Antibody Conjugate to Target Mesothelin for Oncology – Drug Profile 301
MTG-201 – Drug Profile 303
MTG-202 – Drug Profile 305
napabucasin – Drug Profile 306
NGR-hTNF – Drug Profile 314
nintedanib – Drug Profile 320
nivolumab – Drug Profile 331
Oncolytic Virus for Malignant Pleural Mesothelioma – Drug Profile 372
Oncolytic Virus to Target CD46 and SLC5A5 for Malignant Pleural Mesothelioma – Drug Profile 373
ONCOS-102 – Drug Profile 374
OSE-2101 – Drug Profile 377
Oshadi D + Oshadi R – Drug Profile 380
OXB-301 – Drug Profile 381
P-0005091 – Drug Profile 385
pegargiminase – Drug Profile 386
pembrolizumab – Drug Profile 395
pemetrexed disodium – Drug Profile 443
porfimer sodium – Drug Profile 444
rAd-IFN – Drug Profile 446
RG-7787 – Drug Profile 449
S-588210 – Drug Profile 451
Small Molecule for Malignant Mesothelioma and Asbestosis – Drug Profile 452
Small Molecule for Oncology – Drug Profile 453
Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Metastatic Lung Cancer – Drug Profile 454
TargomiRs – Drug Profile 455
tazemetostat – Drug Profile 457
TB-535 – Drug Profile 466
Teleukin – Drug Profile 467
tivantinib – Drug Profile 469
trabectedin – Drug Profile 475
TRC-102 – Drug Profile 482
Vaccine to target Mesothelin for Mesothelioma and Ovarian Cancer – Drug Profile 484
Vaccine to Target WT1 for Oncology – Drug Profile 485
Vas-01 – Drug Profile 486
YS-110 – Drug Profile 488
Malignant Mesothelioma – Dormant Projects 490
Malignant Mesothelioma – Discontinued Products 492
Malignant Mesothelioma – Product Development Milestones 493
Featured News & Press Releases 493
Appendix 504
Methodology 504
Coverage 504
Secondary Research 504
Primary Research 504
Expert Panel Validation 504
Contact Us 504
Disclaimer 505
List of Tables
Number of Products under Development for Malignant Mesothelioma, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Malignant Mesothelioma – Pipeline by Aduro BioTech Inc, H1 2017
Malignant Mesothelioma – Pipeline by Advantagene Inc, H1 2017
Malignant Mesothelioma – Pipeline by Amphera BV, H1 2017
Malignant Mesothelioma – Pipeline by AnGes MG Inc, H1 2017
Malignant Mesothelioma – Pipeline by arGEN-X BV, H1 2017
Malignant Mesothelioma – Pipeline by ArQule Inc, H1 2017
Malignant Mesothelioma – Pipeline by AVEO Pharmaceuticals Inc, H1 2017
Malignant Mesothelioma – Pipeline by Bayer AG, H1 2017
Malignant Mesothelioma – Pipeline by Biogen Inc, H1 2017
Malignant Mesothelioma – Pipeline by Bionomics Ltd, H1 2017
Malignant Mesothelioma – Pipeline by Biotecnol Ltd, H1 2017
Malignant Mesothelioma – Pipeline by Boehringer Ingelheim GmbH, H1 2017
Malignant Mesothelioma – Pipeline by Boston Biomedical Inc, H1 2017
Malignant Mesothelioma – Pipeline by Bristol-Myers Squibb Company, H1 2017
Malignant Mesothelioma – Pipeline by Calithera Biosciences Inc, H1 2017
Malignant Mesothelioma – Pipeline by CanBas Co Ltd, H1 2017
Malignant Mesothelioma – Pipeline by CBT Pharmaceuticals Inc, H1 2017
Malignant Mesothelioma – Pipeline by Concordia International Corp, H1 2017
Malignant Mesothelioma – Pipeline by Eagle Pharmaceuticals Inc, H1 2017
Malignant Mesothelioma – Pipeline by Eisai Co Ltd, H1 2017
Malignant Mesothelioma – Pipeline by Eli Lilly and Company, H1 2017
Malignant Mesothelioma – Pipeline by EnGeneIC Ltd, H1 2017
Malignant Mesothelioma – Pipeline by EpiZyme Inc, H1 2017
Malignant Mesothelioma – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Malignant Mesothelioma – Pipeline by Five Prime Therapeutics Inc, H1 2017
Malignant Mesothelioma – Pipeline by Genelux Corp, H1 2017
Malignant Mesothelioma – Pipeline by GlaxoSmithKline Plc, H1 2017
Malignant Mesothelioma – Pipeline by Horizon Pharma Plc, H1 2017
Malignant Mesothelioma – Pipeline by Inventiva, H1 2017
Malignant Mesothelioma – Pipeline by Juno Therapeutics Inc, H1 2017
Malignant Mesothelioma – Pipeline by Karyopharm Therapeutics Inc, H1 2017
Malignant Mesothelioma – Pipeline by MacroGenics Inc, H1 2017
Malignant Mesothelioma – Pipeline by MedImmune LLC, H1 2017
Malignant Mesothelioma – Pipeline by Merck & Co Inc, H1 2017
Malignant Mesothelioma – Pipeline by Merck KGaA, H1 2017
Malignant Mesothelioma – Pipeline by Millennium Pharmaceuticals Inc, H1 2017
Malignant Mesothelioma – Pipeline by MolMed SpA, H1 2017
Malignant Mesothelioma – Pipeline by Morphotek Inc, H1 2017
Malignant Mesothelioma – Pipeline by Novartis AG, H1 2017
Malignant Mesothelioma – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Malignant Mesothelioma – Pipeline by OSE Immunotherapeutics, H1 2017
Malignant Mesothelioma – Pipeline by Oxford BioMedica Plc, H1 2017
Malignant Mesothelioma – Pipeline by Pharma Mar SA, H1 2017
Malignant Mesothelioma – Pipeline by Philogen SpA, H1 2017
Malignant Mesothelioma – Pipeline by Polaris Pharmaceuticals Inc, H1 2017
Malignant Mesothelioma – Pipeline by Progenra Inc, H1 2017
Malignant Mesothelioma – Pipeline by Seattle Genetics Inc, H1 2017
Malignant Mesothelioma – Pipeline by Sellas Inc, H1 2017
Malignant Mesothelioma – Pipeline by Targovax ASA, H1 2017
Malignant Mesothelioma – Pipeline by TRACON Pharmaceuticals Inc, H1 2017
Malignant Mesothelioma – Pipeline by TREAT U SA, H1 2017
Malignant Mesothelioma – Pipeline by UbiVac LLC, H1 2017
Malignant Mesothelioma – Pipeline by VasGene Therapeutics Inc, H1 2017
Malignant Mesothelioma – Pipeline by Verastem Inc, H1 2017
Malignant Mesothelioma – Pipeline by Virttu Biologics Ltd, H1 2017
Malignant Mesothelioma – Pipeline by Vyriad Inc, H1 2017
Malignant Mesothelioma – Pipeline by Y's Therapeutics Co Ltd, H1 2017
Malignant Mesothelioma – Dormant Projects, H1 2017
Malignant Mesothelioma – Dormant Projects, H1 2017 (Contd..1), H1 2017
Malignant Mesothelioma – Discontinued Products, H1 2017
List of Figures
Number of Products under Development for Malignant Mesothelioma, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
